Continuing Education Activity
Varicella-zoster virus (chickenpox) is an acute febrile rash illness that was very common in children in the United States before the universal vaccination program came into existence. Luckily, the varicella-zoster virus is a vaccine-preventable disease. The FDA approves the use of the live varicella virus vaccine to provide immunity for preventing varicella in individuals 12 months older. This activity reviews the mechanism of action, indications, contraindications, adverse effects of this vaccine, and the front-line personnel involved in the prevention of the disease.
Objectives:
Identify the goals of vaccination with the varicella vaccine.
Describe the mechanism of action of the varicella vaccine.
Describe the potential adverse reactions expected following vaccination with the varicella vaccine.
Explain interprofessional team strategies for improving care coordination and communication to advance varicella vaccination and improve patient outcomes.
Indications
Varicellaorchickenpoxis a common and highly contagious exanthematic disease caused by thevaricella-zostervirus (VZV) that during primary infection can establish latency. VZV reactivation, even decades after primary infection, causesherpes zoster. Varicellastill represents the most widespread vaccine-preventable childhood infectious disease in industrialized countries; due to its relevant burden on healthcare resources, several countries have introducedvaricellavaccination into the recommended routine childhood national immunization schedule.[1]
Varicella-zoster virus (chickenpox) was verycommon in children in the United States before the universal vaccination program came into existence.[2]The varicella-zoster virus manifestations are usually verymild and self-limited, but in young infants and adults, the complications can be life-threatening. Luckily,the varicella-zoster virusis a vaccine-preventable disease, and the FDA approves the use of the live varicella virus vaccine to provide immunity for the prevention of varicella in individuals 12 months and older. Current vaccines againstvaricella andherpes zoster are not 100% efficacious; itis between 70%and 90% effectiveat preventing varicella andover 95% effectiveat preventing severe varicella.[3] Specifically, studies have shown that one dose of varicella vaccine can lead to breakthroughvaricella, albeit rarely, in children, and a 2-dose regimen is now recommended.[4] The varicella vaccine is used routinely in children with two doses.
The first dose is givento children between 12 to 15 months of age, and the administration of the second dose is for children between 4 to 6 years old.[5][6]If three months have passed since the first dose, one may opt to give the second dose earlier. If a child has never been vaccinated or had chickenpox, the practitioner should give the two doses at least 28 days apart. One may give the varicella vaccine at the same time as other vaccines; however, evidence demonstrates an increase in the breakthrough disease when the varicella vaccine administration is within four weeks of the measles-mumps-rubella (MMR) vaccine. The recommendation is to give the vaccinessimultaneously in different injection sites or to give them four weeks apart. A quadrivalent combination vaccine also exists called MMRV, which consists of MMR and varicella and may be provided in placeof the two individual doses if the child is younger than 12 years old. The FDA has not approved the use of this vaccine in pregnancy and requires intenseimmune status evaluation in individuals with a family history of congenital immunodeficiencies.[7][8]
The varicella vaccine is now FDA approved to givefor post-exposure use and outbreak control. The vaccine should be given as soon as possible after exposure, but it has shown effectiveness in preventing or modifying disease when given within threeto five days post-exposure.[9] Oral acyclovir administered during the virus's incubation period may also modify varicella disease in a healthy child. However, this practice has not yet been FDA approved and needs further evaluation. There also exists a high-titer anti-varicella virus immune globulin, which can be used asprophylaxis in immunocompromised children, pregnant women, and newborns exposed to varicella. Another indication for prophylaxis with the immune globulin is in close contact with a high-risk susceptible individual and someone who has herpes zoster.[10][11]
You can demonstrate evidence of immunity to varicella by showing documentation. The following documentation will prove age-appropriate vaccination with varicella vaccine:
Preschool-age children (older than 12 months): one dose
School-age children, adolescents, and adults: two doses
Laboratory evidence or confirmation of the disease
Birth in the United States before 1980; unless one is immunocompromised, a pregnant woman, or a health care worker (born before 1980 does not count as evidence of immunity in this population)
Diagnosis or verification of a history of varicella disease by a healthcare provider
Diagnosis or verification of a history of herpes zoster by a healthcare provider
Mechanism of Action
The varicella-zoster vaccine contains live attenuated varicella-zoster vaccine(Oka strain). This vaccine induces both humoral and cell-mediated immune responses. It produces an IgG humoral immune response in individuals, and the cell-mediated immune response is by varicella-zoster-specific activation of both CD4+ T-helper and CD8+ T-lymphocyte cells. The duration of protection is currentlystill unknown; however, there is evidence shown in some efficacy trials that the vaccine can offer continued protection for up to ten years after vaccination.
Administration
The varicella vaccine is only available to be administered subcutaneously. It is best when practitioners inject the vaccine in the outer aspect of the upper arm in the deltoid region or anterolateral thigh.
For adult immunization, the varicella vaccine is administered as 0.5 mL subcutaneously for two doses 4 to 8 weeks apart.
Pediatric Immunization
From 12 months to 12 years: 0.5 mL subcutaneously for one dose between 12 to 15 months, then 0.5 mL subcutaneously between the ages of 4 and 6.
If ages 7 to 12 at series start, the second dose may be administered as soon as4 weeks after the initial dose.
If ages 13 and older at the series start, the vaccine is administered 0.5 mL subcutaneously for 2 doses 4 to 8 weeks apart.
Adverse Effects
Varicella vaccine is safe and well-tolerated. According to some sources, injection site complaints after vaccination were slightly higher after the second dose than the first. The most commonly reported adverse effect is soreness or swelling at the injection site.
Some other mild reported reactionsinclude fever and mild vaccine-associated varicelliform rash. The rash comprises six to ten papular, vesicular, erythematous lesions, which peak around eight to 21 days after injection. It israre, but when an individual has this rash after getting the vaccine, other household members are susceptible to transmission.
Some of the moderatereported reactions include a fever that causes a low-grade seizure (showing jerking or staring), but this is rare and more frequently reported with the MMRV vaccine five to 12 days after the vaccine, and upperrespiratory infection, which can include a cough, chest pain, and difficulty breathing.
Seriousreported reactions include pneumonia, low blood cell count, and severe brain reactions. These are all extremelyrare, and researchers still do not understand if the vaccine causes these reactions.
After administration of the vaccine, it is recommended to avoid salicylates for five weeks due to the risk of Reyessyndrome and to avoid contact with susceptible high-risk individuals.
Contraindications
The varicella vaccine is contraindicated in individuals who have a severe allergy or have had ananaphylactic reaction to neomycin or gelatin, which are components of this vaccine, or to the previous dose of a varicella-containing vaccine.[12][13]
It is also contraindicated in individuals who are immunosuppressed or immunodeficient in any of the following ways:
Severe combined immunodeficiency, lymphoma, leukemia, AIDS, blood dyscrasias, hypogammaglobulinemia, agammaglobulinemia, IgA deficiency, malignant neoplasms affecting the bone marrow or lymphatic system, patients receiving steroids, chemotherapy, or X-rays asa treatment for canceror X-rays
Any patient showing clinical signs of infection with HIV
Any person who has a family history of congenital or hereditary immunodeficiency in first-degree relatives unless there is demonstrable immunocompetence of the potential vaccine recipient
Patients can not receive the vaccine if they present with febrile illness or have active, untreated tuberculosis.
Vaccination is contraindicated in pregnant females, and women should delay pregnancy for three months after vaccination by using effective birth control. Maternal varicella infection has been shown to harm the fetus, but the vaccinationeffects have not had testing on pregnant women, and the effects on fetal development are currentlyunknown. It is also not known whether the varicella vaccine virus passes in breast milk, and it is best to avoid vaccination duringbreastfeedingfor that reason.
Thereis currentlyno clinical data available on the efficacy or the safety of administration of the varicella vaccine in children younger than 12 months old.
Monitoring
No routine tests are recommended in conjunction with this vaccine.
Enhancing Healthcare Team Outcomes
All interprofessional healthcare team members, includingclinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists, are frontline professionalsin preventing chickenpox. Because of the anti-vaccination sentiment in society, healthcare professionals must educate the public on the importance of vaccination.[11] For children who develop an infection, the parents should receive education on trimming the child's fingernails to minimize excoriation marks and bacterialsuperinfections. The pharmacist should warn the parents not to administer aspirin to young children with feverbecause of the risk of Reye syndrome. All pregnant women who develop chickenpox should obtain a referral to an infectious disease specialist regarding treatment. Further, postpartum women with chickenpox should be encouraged to breastfeed if they desire because it is safe.[14][15][Level5]
Outcomes
Chickenpox in a healthy individual is a self-limiting illness with an excellent outcome. However, in immunocompromised individuals, the infection can be associated with very high morbidity and mortality. The currentlyavailable Varicella vaccine is safe and well-tolerated. According to some sources, injection site complaints after vaccination were slightly higher after the second dose than the first. The most commonly reported adverse effect is soreness or swelling at the injection site.[16][17] [Level 5]
Varicella/herpes zoster vaccines require the collaboration of the entire interprofessional healthcare team. In many states, pharmacists are empowered to administer the vaccine in the pharmacy, and they must let the patient's physician know so records can be updated appropriately. Physicians, nurses, and pharmacists all bear responsibility for patient counseling and ensuring the patient is a viable vaccine candidate, in line with the restrictions outlined above. Should they encounter any of these contraindications, they must communicate them to the entire healthcare team so all members are on the same page and patient records can be updated. This interprofessional approach ensures maximal effectiveness for varicella/herpes zoster vaccination strategies. [Level 5]
References
- 1.
Gabutti G, Franchi M, Maniscalco L, Stefanati A. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs. Minerva Pediatr. 2016 Jun;68(3):213-25. [PubMed: 27125440]
- 2.
Ong CY, Low SG, Vasanwala FF, Baikunje S, Low LL. Varicella infections in patients with end stage renal disease: a systematic review. BMC Nephrol. 2018 Jul 24;19(1):185. [PMC free article: PMC6057025] [PubMed: 30041621]
- 3.
American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics. 2007 Jul;120(1):221-31. [PubMed: 17606582]
- 4.
Haberthur K, Engelmann F, Park B, Barron A, Legasse A, Dewane J, Fischer M, Kerns A, Brown M, Messaoudi I. CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog. 2011 Nov;7(11):e1002367. [PMC free article: PMC3213099] [PubMed: 22102814]
- 5.
Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917. [PMC free article: PMC6107323] [PubMed: 30138305]
- 6.
Gray SJ, Cathie K. Fifteen-minute consultation: Chickenpox vaccine-should parents immunise their children privately? Arch Dis Child Educ Pract Ed. 2019 Jun;104(3):120-123. [PubMed: 30077987]
- 7.
Lo Presti C, Curti C, Montana M, Bornet C, Vanelle P. Chickenpox: An update. Med Mal Infect. 2019 Feb;49(1):1-8. [PubMed: 29789159]
- 8.
Chan DYW, Edmunds WJ, Chan HL, Chan V, Lam YCK, Thomas SL, van Hoek AJ, Flasche S. The changing epidemiology of varicella and herpes zoster in Hong Kong before universal varicella vaccination in 2014. Epidemiol Infect. 2018 Apr;146(6):723-734. [PMC free article: PMC6533643] [PubMed: 29526171]
- 9.
Varicella and herpes zoster vaccines: WHO position paper, June 2014--Recommendations. Vaccine. 2016 Jan 04;34(2):198-199. [PubMed: 26723191]
- 10.
Doret M, Marcellin L. [Vaccination in the early post-partum: Guidelines]. J Gynecol Obstet Biol Reprod (Paris). 2015 Dec;44(10):1135-40. [PubMed: 26518154]
- 11.
Baracco GJ, Eisert S, Saavedra S, Hirsch P, Marin M, Ortega-Sanchez IR. Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel. Am J Infect Control. 2015 Oct 01;43(10):1053-60. [PubMed: 26138999]
- 12.
Malaiya R, Patel S, Snowden N, Leventis P. Varicella vaccination in the immunocompromised. Rheumatology (Oxford). 2015 Apr;54(4):567-9. [PubMed: 24758889]
- 13.
Dolan SB, Libby TE, Lindley MC, Ahmed F, Stevenson J, Strikas RA. Vaccination policies among health professional schools: evidence of immunity and allowance of vaccination exemptions. Infect Control Hosp Epidemiol. 2015 Feb;36(2):186-91. [PMC free article: PMC6200321] [PubMed: 25633001]
- 14.
Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep. 2013 Jul 19;62(28):574-6. [PMC free article: PMC4604813] [PubMed: 23863705]
- 15.
Lopez AS, Cardemil C, Pabst LJ, Cullen KA, Leung J, Bialek SR., Division of Viral Diseases. Centers for Disease Control and Prevention (CDC). Two-dose varicella vaccination coverage among children aged 7 years--six sentinel sites, United States, 2006-2012. MMWR Morb Mortal Wkly Rep. 2014 Feb 28;63(8):174-7. [PMC free article: PMC4584524] [PubMed: 24572613]
- 16.
Ackerson BK, Li BH, Sy LS, Cheetham TC, Jacobsen SJ. Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers. Vaccine. 2014 Apr 01;32(16):1863-8. [PubMed: 24508041]
- 17.
Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013 Feb;31(2):125-36. [PubMed: 23335045]
Disclosure: Vasudha Kota declares no relevant financial relationships with ineligible companies.
Disclosure: Marc Grella declares no relevant financial relationships with ineligible companies.
